 Biogen stock was muted late Tuesday after Eisai unveiled Alzheimers treatment results likely to spark a debate over the drugs benefits. The post Why This New Alzheimers Update Is Likely To Spark A Debate For Biogen Investors appeared first on Investors Business Daily. 